Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis

Giovanni Broggi, Paolo Ferroli, Angelo Franzini, Domenico Servello, Ivano Dones

Abstract

Objective—To examine surgical findings and results of microvascular decompression (MVD) for trigeminal neuralgia (TN), including patients with multiple sclerosis, to bring new insight about the role of microvascular compression in the pathogenesis of the disorder and the role of MVD in its treatment.

Methods—Between 1990 and 1998, 250 patients affected by trigeminal neuralgia underwent MVD in the Department of Neurosurgery of the “Istituto Nazionale Neurologico C Besta” in Milan. Limiting the review to the period 1991–6, to exclude the “learning period” (the first 50 cases) and patients with less than 1 year follow up, surgical findings and results were critically analysed in 148 consecutive cases, including 10 patients with multiple sclerosis.

Results—Vascular compression of the trigeminal nerve was found in all cases. The recurrence rate was 15.3% (follow up 1–7 years, mean 38 months). In five of 10 patients with multiple sclerosis an excellent result was achieved (follow up 12–39 months, mean 24 months). Patients with TN for more than 84 months did significantly worse than those with a shorter history (p<0.05). There was no mortality and most complications occurred in the learning period. Surgical complications were not related to age of the patients.

Conclusions—Aetiopathogenesis of trigeminal neuralgia remains a mystery. These findings suggest a common neuromodulatory role of microvascular compression in both patients with or without multiple sclerosis rather than a direct causal role. MVD was found to be a safe and effective procedure to relieve typical TN in patients of all ages. It should be proposed as first choice surgery to all patients affected by TN, even in selected cases with multiple sclerosis, to give them the opportunity of pain relief without sensory deficits.

Keywords: trigeminal neuralgia; microvascular decompression; multiple sclerosis

The concept of microvascular compression of the trigeminal nerve described by Dandy in 1934,1 rediscovered by Gardner and Miklos,2 and fully recognised and popularised by Jannetta3 was a milestone in the management of medically intractable trigeminal neuralgia. In the past 30 years thousands of patients have undergone successful microvascular decompression and today it represents one of the most widely used surgical options for trigeminal neuralgia. Several studies agree on high rate of long term success and even authors against the concept of microvascular compression perform it for its effectiveness.4 Controversies still exist about the role of vascular compression in the pathogenesis of the disorder, the possible involvement of the same mechanism also in patients affected by multiple sclerosis, the existence of reliable prognostic factors, and the role of microvascular decompression in elderly patients.

To bring new insight about these topics we critically reviewed 250 patients, including 10 patients affected by multiple sclerosis, all operated on by the same surgeon (GB).

Patients and methods

Between 1990 and 1998, 250 patients affected by trigeminal neuralgia (TN) underwent microvascular decompression (MVD) in the Department of Neurosurgery of the “Istituto Nazionale Neurologico C. Besta” in Milan. Our review was limited to 146 patients treated in the period 1991-October 1996. Those patients with less than 1 year follow up and the first 50 cases (the “learning period”), in which a slightly different surgical technique was used, were excluded. In 10 cases TN was associated with multiple sclerosis, clinically diagnosed and proved by MRI and CSF examination. Individual symptoms, clinical history, operative findings, and complications were recorded. Operative results were assessed by clinical follow up and periodic phone surveys. The outcome of intervention was graded by an independent reviewer other than the operating surgeon.

All of these patients had been given previous medical therapy (carbamazepine, diphenylhydantoin, baclofen), to which they had become refractory or intolerant. Contrast enhanced CT and MRI were routinely performed to exclude cerebellopontine angle mass lesions, to find signs of demyelinating disease or neurovascular compression. As most cases had had MRI in other hospitals, sequences varied and specific studies such as magnetic resonance tomographic angiography were used in only 17 patients. The presence of a demyelinating plaque in the trigeminal root entry zone (REZ), pontine tract, and nuclei was considered a contraindication to open surgery. The
failure to image microvascular compression with MRI was not considered sufficient to exclude patients from MVD, because of the possibility of false negatives.

SURGICAL TECHNIQUE
Exploration of the cerebellopontine angle was performed by GB through a small, keyhole type (less than 20 mm diameter) retromastoid craniectomy, with patients in the supine position with the head rotated to the side opposite the neuralgia. The margins of transverse sinus and sigmoid sinuses were exposed and the dura was opened along the line bisecting their angle. The fifth cranial nerve was exposed through a supracerebellar approach, thus avoiding lateral retraction of the cerebellar hemisphere and traction of the VII-VIII complex of cranial nerves. Neither lumbar CSF drainage nor mannitol were used to avoid anatomical modification before dural opening. In approaching the trigeminal nerve, care was taken to spare at least two petrous veins. The nerve was cautiously dissected free without unnecessary manipulation. Any compressive arteries were relocated away from the trigeminal nerve and its root entry zone in the pons by the use of small pieces of teflon. Compressive veins were electrocoagulated and divided. In the “learning period” a greater craniectomy (about 35 mm diameter), a wider dural opening, and a lateral cerebellar approach with a self retaining retractor were used. As previously reported,7 brain stem auditory evoked potentials were recorded in 98 cases (37 during the “learning period” and 61 in subsequent cases).

STATISTICAL ANALYSIS
A statistical analysis of “essential” TN group (n=136) was used to relate the likelihood of postoperative recurrence of tic to the following variables: patient’s age and sex; involved side and branch; duration of symptoms; history of previous trigeminal ablative procedures; type of neurovascular compression (arterial, venous, or both); postoperative numbness, and hypertension. Continuous data were compared using a two sample t test; discrete data were compared using $\chi^2$ or Fisher’s exact test, as appropriate. Recurrence free curves were compared by log rank test.

Results
The follow up ranged from 1 to 7 years (mean 38 months). The report includes 75 female patients and 71 male patients ranging in age from 20 to 76 years (mean 56 years). The right side of the face was affected in 81 cases and the left side in 67. In two patients both sides of the face were involved at different times. The branch distribution to which pain was referred was: V1 only, one case (0.6%); V2 only, 26 cases (17%); V3 only, 32 cases (21.4%); V1 and V2, 30 cases (20.5%); V2 and V3, 43 cases (29.5%); and V1, V2, and V3, 16 cases (11%). Duration of preoperative symptoms ranged between 3 months and 35 years (mean 8.5 years). Half of the patients had TN for more than 7 years. Sixty six patients had undergone previous procedures affecting the nerve such as radiofrequency thermal rhizotomy, balloon microcompression, glycerol rhizotomy, alcohol injection, or peripheral avulsion (one procedure in 35, two in 16, three in five, four in two, and five in two patients). The longer the clinical history, the more likely that previous procedures had been performed and more branches were involved. Arterial hypertension was associated with trigeminal neuralgia in 40 patients (27%). Two patients had bilateral TN, so 148 affected sides were initially operated on. Seven patients required a second operation for a total of 155 MVDs. At the first operation a microvascular compression at the trigeminal REZ was found in all patients: severe, with a clear groove on the trigeminal root in 133 cases, slight, with a vascular contact not distorting the root in 15. In 138 cases of “essential” TN it was arterial in 70, venous in 18, and both arterial and venous in 50. In 10 patients with multiple sclerosis it was arterial in five, venous in three, and arteriovenous in two. In 12 patients (three with multiple sclerosis) an arachnoiditis coexisted; in four cases vascular compression occurred well beyond the REZ.; in 13 the trigeminal nerve seemed to be shorter than usual and in five an asymptomatic microvascular compression of the V1 and V2 was found.

The stabbing paroxysmal pain typical of trigeminal neuralgia disappeared immediately after surgery in 126 (85%) out of 148 initially operated sides and faded away within 2 weeks in another 11 (7.5%). In 11 patients (7.5%) pain paroxysms remained unchanged postoperatively (detail for patients with multiple sclerosis: nine of 10 immediately pain free; one of 10 unchanged).

Seven patients were lost and long term follow up was available in 141 of 148 cases. Postoperative relief from TN was complete without medication in 101 (71%), good with rare and slight paroxysms not requiring medication, in one (0.7%); partial, requiring lower dosage of drugs, in 13 (9%); and absent in 22 (15.3%). In detail for patients with multiple sclerosis (follow up 12–39 months, average 24) it was complete in five of 10, partial in one of 10, and absent in four of 10.

Seven patients affected by “essential” TN needed a second MVD during follow up, for a drug resistant recurrence. Complete relief from pain, without medication, was achieved in four cases (findings at repeated surgery: incomplete decompression in two cases; new trigeminal venous compression in one case with sigmoid sinus thrombosis evident at pre-operative MRI, and thick arachnoiditis with a vein adherent to the trigeminal REZ in the remaining case). One patient had a drug resistant recurrence two months after the second MVD (arachnoiditis and venous compression). In two patients pain paroxysm remained unchanged (venous compression in one case, arachnoiditis and venous compression in the other). The general recurrence free curve is shown in figure 1. To verify the hypothesis that the duration of clinical history was related to the outcome we searched through 1 year, 2 years, 3 years, 4 years, etc. We reached significance at 7 years. Comparison of
cumulative probability of being recurrence free by a shorter or longer than 7 year clinical history is shown in figure 2. No other statistically significant factors predicting long term relief from tic after MDV were identified. A comparison between multiple sclerosis group and “essential” TN group or between cases with a slight compression and a severe compression without root distortion; complete relief in 12 of 15, partial relief in two of 15, no relief in one of 15).

Operative complications are shown in table 1. There was no surgical mortality in this series. In two patients with a pre-existent severe trigeminal sensorial deficit and atypical neuralgia the disappearance of pain paroxysms was followed by a painful dysesthesia requiring treatment with tricyclic antidepressant drugs or related medication for burning or aching pain. Out of 87 patients without previous ipsilateral procedures there was a slight permanent trigeminal sensorial deficit in three.

Seventeen patients out of 250 had ipsilateral hearing loss; mild (shown only by postoperative audiometric examination) in nine, and severe (clinically evident) in eight. No patient had permanent facial weakness. Six patients had postoperative diplopia, transient in all cases. A CSF rhinorrhoea required a 3d a y external spinal drainage in seven cases and reoperation in five. As shown in table 1, most of the morbidities appeared during the learning period.

Comparison between the incidence of surgical complications in different ages (more than 65 year old v less than 65 year old) did not show any statistically significant difference.

Discussion

New drugs have been recently introduced in the treatment of trigeminal neuralgia6–10 and perhaps the number of surgical candidates will decrease, but carbamazepine and phenytoin
are the only drugs with established efficacy. Due to relapse about half of all patients eventually require an operation for pain relief. 11 No other selection criteria for surgery than refractoriness to medical therapy was used in case of typical trigeminal “tic douloureux”. MVD was proposed to patients affected by MS only in the absence of plaques demonstrated by MRI in the trigeminal REZ, pontine tract, and nuclei. MRI can be an extremely accurate tool for detecting neurovascular compression, 12 but the absence of an MRI identified neurovascular compression should not exclude the patient with intractable pain from open surgery because of the possibility of false negative MRI studies, even with high definition MR tomographic angiography (personal observation and Meany et al 22). In the literature there are several series reporting data on the efficacy of MVD (table 2). Direct comparison of results is difficult because of different durations of follow up and differing definitions of operative success. Considering the number of completely pain free patients at long term follow up, our results (74% of completely pain free patients at 5 year follow up) are in the range (53%-94%) of other reported series and in particular are similar to those of Barker and Jannetta 24 and of other series using actuarial methods. 15 16 23 Similar results (39 of 50 patients completely pain free at 7 year follow up) but with a higher rate of early re-exploration for inadequate decompression (four patients successfully re-operated on within the first month for persistent pain), were achieved in the first 50 cases, although with a slightly different surgical technique. Coakham and Moss 27 recently reported better results, with only a 10% relapse rate in their 17 year follow up study of more than 150 patients. They achieved such results using a careful surgical technique and perfect haemostasis. 28

Table 3 MVD: mortality and long term side effects

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>No of patients</th>
<th>Mortality</th>
<th>Cereb Inf</th>
<th>Def VII</th>
<th>Def VIP</th>
<th>Def PD</th>
<th>Dipl</th>
<th>Def V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taarnhoj et al 1982</td>
<td>350</td>
<td>2 (1.1%)</td>
<td>0.3%</td>
<td>1.4%</td>
<td>0.6%</td>
<td>0.3%</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Barba and Allone 1984</td>
<td>37</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Zorman and Wilson 1984</td>
<td>125</td>
<td>0</td>
<td>0</td>
<td>3%</td>
<td>3%</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Szapiro et al 1985</td>
<td>70</td>
<td>1 (1.4%)</td>
<td>1.4%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bederson and Wilson 1989</td>
<td>252</td>
<td>2 (0.7%)</td>
<td>0</td>
<td>3%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dagle et al 1989</td>
<td>57</td>
<td>1 (1.7%)</td>
<td>1%</td>
<td>0</td>
<td>0</td>
<td>1.7%</td>
<td>1.7%</td>
<td>0</td>
</tr>
<tr>
<td>Sindou et al 1990</td>
<td>60</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Klun 1992</td>
<td>220</td>
<td>3 (1.3%)</td>
<td>0</td>
<td>0.4%</td>
<td>0</td>
<td>0</td>
<td>1.5%</td>
<td>1.5%</td>
</tr>
<tr>
<td>Sun et al 1994</td>
<td>61</td>
<td>0</td>
<td>0</td>
<td>1.5%</td>
<td>0</td>
<td>0</td>
<td>1.5%</td>
<td>1.5%</td>
</tr>
<tr>
<td>Meneses et al 1995</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pamir et al 1995</td>
<td>32</td>
<td>0</td>
<td>3%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mendoza and Illingworth 1996</td>
<td>133</td>
<td>1 (0.7%)</td>
<td>1.4%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Barker et al 1996</td>
<td>1336</td>
<td>2 (0.2%)</td>
<td>1%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Present report 1998</td>
<td>250</td>
<td>0</td>
<td>0.4%</td>
<td>3.2%</td>
<td>0</td>
<td>0</td>
<td>1.2%</td>
<td>0</td>
</tr>
</tbody>
</table>

Cereb inf= cerebellar infarct; Def=deficit; Dipl=diplopia; PD=painful dysaesthesia.

Some of the criticisms about MVD are based on presumed high mortality and morbidity. In our series there was no mortality and no permanent morbidity. Ataxia, disequilibrium, and gait disturbances sometimes found in the early postoperative period, at hospital discharge (3 days after operation), fully recovered within 2 weeks without rehabilitation. Collecting data from the literature series on more than 3000 published cases (table 3) the mortality rate is 0.3% (12 of 3033). Cranial nerve morbidity is reported, but generally diplopia, dysphagia, facial weakness, vertigo, and trigeminal hypoesthesia are all transient. Injury to the acoustic branch of the VIII cranial nerve is the only relevant long term cranial nerve dysfunction reported in several series, ranging from 0.1% to 3% (table 3). We recorded brain stem acoustic evoked potentials during MVD in 98 consecutive procedures. Although no clear correlation could be found between the increase in latency, the reduction in amplitude and the degree of hearing loss, 15 a direct relation between some surgical manoeuvres and brain stem acoustic evoked potentials significant changes was found and led us to a mini-invasive supracerebellar approach. In the 200 cases operated on through this approach, we had only three cases of severe hypoaucisia, always related to a particular surgical problem (bleeding from petrous bridge vein in one case, troublesome dissection from the pons of a dolicocegalbasilar artery invaginating the trigeminal and the facial nerve in two cases). Probably this is the only complication that cannot be prevented in all cases because of the extreme vulnerability of the internal auditory artery and its colear branches. Other reported complications such as CSF leakage, haemotympanum, sigmoid sinus thrombosis, cerebellar infarct, and haematoma can be avoided with a careful surgical technique and perfect haemostasis. In a patient in our series, sigmoid sinus thrombosis was found associated with a new venous trigeminal compression. We did not find any age related statistically significant difference in incidence of surgical complications and so we perform MVD without an absolute age limit. Furthermore, in elderly patients surgical exposure of cerebellopontine
angle is easier due to atrophy, and the postoperative course was generally uneventful with early mobilisation.

Among other less invasive surgical procedures, but all causing more or less controlled injury to the trigeminal nerve, root, or ganglion, only radiofrequency rhizotomy, as recently pointed out by Taha and Tew,\(^4\) has pain recurrence rates similar to that of MVD. Unfortunately this result can be accomplished only at the cost of a sensorial deficit which is far from negligible and not well tolerated in some patients.

Multiple sclerosis has long been considered a contraindication to MVD because of supposed origin from a demyelinating plaque in the central trigeminal pathways\(^1\) or in the trigeminal REZ.\(^5\) In the literature only a few patients with multiple sclerosis who underwent MVD for trigeminal neuralgia can be found and results are contradictory.\(^6\) \(^7\) \(^8\) In our series five of 10 patients did well with a follow up of 12–39 months. Although the small series and the short follow up may not allow definitive conclusions, our results suggest that it may be worthwhile not depriving patients with MS of a potential cure. Further studies are needed to better evaluate the role of MVD for trigeminal neuralgia in patients with MS.

A peripheral hypothesis,\(^9\) \(^10\) \(^11\) and more recently, theories trying to reconcile central and peripheral hypotheses\(^12\) \(^13\) about aetiopathogenesis of trigeminal neuralgia have been invoked. Nevertheless it remains a mystery. Vascular cross compression is now increasingly accepted as an important aetiological factor. We found a vascular contact in all cases, even in patients with multiple sclerosis. Sometimes the involved vessels are subtle and the root does not seem grossly compressed. In operated cases a missed vessel, a new compressing vessel (an intratraenigmal vein in a patient in our series with sigmoid sinus thrombosis\(^1\) at preoperative MRI) or a telot meditated compression can be seen, but sometimes only an arachnoiditis is found. A similar arachnoiditis can be found when operating on patients, previously operated on for lesions in the cerebellopontine angle and who do not have trigeminal neuralgia. This apparent contradiction and many others (different rates of vascular compressions in different series, patients having trigeminal neuralgia with little or no vascular compression, evidence of vascular compression without neuralgia, vascular compression of the motor branch without hemimasticatory spasm, patients certainly well decompressed with persistent pain etc\(^14\) \(^15\) \(^16\) can be partially explained by different patient selection and different observers. Collectively they mean that the problem of neurovascular compression cannot be considered as a simple cause-effect mechanism. A central involvement of trigeminal pathways with a delicate balance between abnormal and physiological inputs coming from the damaged root and modified excitability of neurons of the trigeminal nucleus must also be considered. The concept of a central neuromodulatory role of impulses coming from the area of cross compression also explains the possibility that a long lasting alteration of discharge modalities of the trigeminal root can cause lowering of the pain threshold as suggested by recent reports on extratrigeminal neurovascular conflicts.\(^17\) \(^18\) MVD certainly acts on pain modulation by peripheral pathological impulses and even if it could not be considered as the “definitive aetiological cure”\(^19\) it certainly is one of the best rational therapeutic options for treatment of trigeminal neuralgia.

Conclusions

According to our large experience with both open surgery and percutaneous techniques,\(^20\) MVD is a safe and effective method for relieving typical TN in patients of all ages. It should be proposed as first choice surgery to all patients affected by TN. Preoperative MRI examination is mandatory to exclude nonvascular trigeminal compression. Sigmoid sinus thrombosis can affect outcome by causing a new venous compression. The recurrence rate seems to be higher in patients with MS and in those patients with a longer clinical history.

We thank Dr A Solarì and Miss M Farinotti for statistical analysis. We are grateful to Miss Lucy Wachendorfer for her assistance in reviewing the English manuscript.


Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis

Giovanni Broggi, Paolo Ferroli, Angelo Franzini, Domenico Servello and Ivano Dones

*J Neurol Neurosurg Psychiatry* 2000 68: 59-64
doi: 10.1136/jnnp.68.1.59

Updated information and services can be found at:
http://jnnp.bmj.com/content/68/1/59

These include:

**References**

This article cites 42 articles, 4 of which you can access for free at:
http://jnnp.bmj.com/content/68/1/59#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Cranial nerves (501)
- Neuromuscular disease (1268)
- Pain (neurology) (711)
- Peripheral nerve disease (614)
- Immunology (including allergy) (1847)
- Multiple sclerosis (889)
- Pain (anaesthesia) (34)
- Pain (palliative care) (39)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/